• FutureMedicine

    Driven by nucleoside R&D to challenge the unmet needs

  • First in Class

    New treatments with unique mechanism of action for patients

  • FOCUS™

    Drug discoveries based on Nucleoside Library Platform

/

Core technology Nucleoside

The core competitiveness of Future Medicine is that it has its own Nuleoside Library platform.

Nucleoside

Lorem ipsum dolor sit amet, consectetur

Platform-FOCUS™

Lorem ipsum dolor sit amet, consectetur

Pipeline

Pipeline Indication Discovery Lead
Optimization
Pre-clinical Phase1 Phase2 Phase3 NDA
FM101 Non-alcoholic steatohepatitis
Glaucoma
Diabetic nephropathy
Primary biliary cholangitis
FM203 Viral disease (CHIKV, COVID, ZIKA)
FM301 Metastatic and resistant pancreatic cancer
FM401 Solid tumor
FM503 Autoimmune disease
Hematologic cancer
FM701 Non small cell lung carcinoma
Pipeline Indication Graph
FM101 Non-alcoholic steatohepatitis

Phase2

Glaucoma

Phase2

Diabetic nephropathy

Phase1

Primary biliary cholangitis

Phase1

FM203 Viral disease (CHIKV, COVID, ZIKA)

Pre-Clinical

FM301 Metastatic and resistant pancreatic cancer

Pre-Clinical

FM401 Solid tumor

Pre-Clinical

FM503 Autoimmune disease

Pre-Clinical

Hematologic cancer

Pre-Clinical

FM701 Non small cell lung carcinoma

Pre-Clinical

Pipeline Indication Graph
FM101 Non-alcoholic steatohepatitis

Phase2

Glaucoma

Phase2

Diabetic nephropathy

Phase1

Primary biliary cholangitis

Phase1

FM203 Viral disease (CHIKV, COVID, ZIKA)

Pre-Clinical

FM301 Metastatic and resistant pancreatic cancer

Pre-Clinical

FM401 Solid tumor

Pre-Clinical

FM503 Autoimmune disease

Pre-Clinical

Hematologic cancer

Pre-Clinical

FM701 Non small cell lung carcinoma

Pre-Clinical

Press Release

No posts have been submitted.